Analyst Price Targets — VTGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 17, 2025 7:21 pm | Andrew Tsai | Jefferies | $0.90 | $0.86 | StreetInsider | Jefferies Downgrades VistaGen Therapeutics (VTGN) to Hold |
| December 17, 2025 3:48 pm | — | Stifel Nicolaus | $1.00 | $0.79 | TheFly | Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints |
| November 17, 2025 2:26 pm | Paul Mattheis | Stifel Nicolaus | $12.00 | $4.60 | StreetInsider | Stifel Reiterates Buy Rating on VistaGen Therapeutics (VTGN) |
| July 22, 2022 11:35 am | Andrew Tsai | Jefferies | $6.00 | $4.38 | TheFly | VistaGen Therapeutics downgraded to Hold from Buy at Jefferies |
Latest News for VTGN
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the overall study population.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of the PALISADE-4 Phase 3 trial of intranasal fasedienol for the acute treatment of social anxiety disorder.…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2026, and provided a corporate update. "We made meaningful progress in fiscal…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company's clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VTGN.
U.S. House Trading
No House trades found for VTGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.